Asia-Pacific Oligonucleotides Synthesis Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Asia-Pacific Oligonucleotides Synthesis Market Size

• The Asia-Pacific oligonucleotides synthesis market size was valued at USD 2.83 billion in 2024 and is expected to reach USD 10.28 billion by 2032, at a CAGR of 17.50% during the forecast period
• The market growth for oligonucleotides synthesis in the Asia-Pacific region is largely fueled by the burgeoning biotechnology and pharmaceutical industries, coupled with rapid advancements in genomics research and molecular diagnostics, leading to increased demand for synthetic nucleic acids in both academic and industrial settings
• Furthermore, rising investments in personalized medicine, gene therapy, and the development of oligonucleotide-based therapeutics (such as antisense oligonucleotides and siRNAs) are establishing oligonucleotides synthesis as a critical component of modern drug discovery and development. These converging factors are accelerating the uptake of oligonucleotides synthesis solutions across the Asia-Pacific region, thereby significantly boosting the industry's growth

Asia-Pacific Oligonucleotides Synthesis Market Analysis

• The Asia-Pacific oligonucleotides synthesis market is a rapidly expanding sector within the broader life sciences industry, driven by the increasing application of synthetic nucleic acids in diverse fields such as drug discovery, molecular diagnostics, and genetic engineering. This growth is significantly fuelled by the region's expanding biopharmaceutical sector and rising investments in R&D
• The escalating demand for oligonucleotides is primarily driven by the widespread adoption of genomics research, growing focus on personalized medicine and gene therapies, and a rising preference for precise and highly specific molecular tools in diagnostics and therapeutics. These converging factors are accelerating the uptake of oligonucleotides synthesis solutions, thereby significantly boosting the industry's growth across Asia-Pacific
• China dominates the Asia-Pacific oligonucleotides synthesis market, with a market share of 37.5% supported by large-scale production facilities, growing domestic demand for precision medicine, and active government initiatives in synthetic biology
• India is expected to witness the highest CAGR of 14.2% in the Asia-Pacific oligonucleotides synthesis market driven by its expanding pharmaceutical industry, increasing focus on genomic research, and strong support through national biotechnology initiatives
• Synthesized oligonucleotide products segment dominates the Asia-Pacific oligonucleotides synthesis market with a market share of 49.50% in 2024. This dominance is driven by the direct demand for custom and catalog oligonucleotides used across various applications, including gene synthesis, PCR primers, siRNA, and antisense oligonucleotides

Report Scope and Asia-Pacific Oligonucleotides Synthesis Market Segmentation

Asia-Pacific Oligonucleotides Synthesis Market Trends

“Growing Demand for Precision Therapeutics and Customization”

• A significant and accelerating trend in the Asia-Pacific oligonucleotides synthesis market is the increasing demand for personalized medicine and targeted therapies. This shift is driving the need for high-quality, custom oligonucleotide synthesis solutions that cater to specific research and clinical requirements
  • For instance, leading players in the region, such as Bioneer Corporation and Kaneka Eurogentec, are expanding their custom oligonucleotide portfolios to meet growing demands from biotechnology and pharmaceutical firms working on gene editing, antisense therapies, and mRNA technologies
• Technological advancements in automated synthesizers and high-throughput synthesis platforms are further supporting this trend, enabling researchers to produce large volumes of high-fidelity oligonucleotides with greater speed and accuracy
• The rise in government funding and private investment in genomic research across countries such as China, Japan, South Korea, and India is contributing significantly to market growth. National initiatives focused on genomics and biopharma innovation are fueling demand for oligonucleotide-based tools in both diagnostics and therapeutics
• Moreover, increasing collaborations between academic institutions and commercial suppliers are streamlining the translation of genomic research into clinical applications, boosting the adoption of synthesized oligonucleotides in molecular diagnostics and drug development pipelines
• The demand for customized, high-purity oligonucleotides is expected to surge as precision medicine gains ground in Asia-Pacific, making oligonucleotide synthesis a cornerstone technology in next-generation healthcare solutions

Asia-Pacific Oligonucleotides Synthesis Market Dynamics

Driver

“Rising Demand for Genomic Medicine and Biotech Innovation”

• • The Asia-Pacific oligonucleotides synthesis market is witnessing robust growth, driven by the rising demand for advanced genetic testing, precision medicine, and personalized therapeutics across the region
    • For instance, in 2024, several biotech firms in south korea and singapore announced collaborations with research institutes to accelerate the development of oligonucleotide-based drugs for rare and chronic diseases. these initiatives reflect a strong push toward next-generation molecular tools, bolstering industry growth
  • Increasing awareness of genetic disorders and cancer diagnostics is further elevating the need for accurate, high-throughput oligonucleotide synthesis platforms to support clinical and research applications
  • In parallel, favorable government initiatives and funding for genomic research in countries such as China, India, and Japan are enabling academic institutions and startups to expand their capabilities in molecular diagnostics, CRISPR-based gene editing, and antisense therapies
  • The market is also benefiting from an expanding base of contract manufacturing organizations (CMOs) and custom synthesis providers, which offer cost-effective, scalable solutions to regional biotech and pharmaceutical firms

Restraint/Challenge

“High Operational Costs and Regulatory Complexity”

• Despite strong growth prospects, the Asia-Pacific oligonucleotides synthesis market faces challenges related to high operational costs and the complexity of regulatory approval processes, particularly in emerging economies
  • For instance, the cost of maintaining purity, scalability, and GMP compliance in oligonucleotide manufacturing facilities is substantial, often deterring smaller players from entering the market
• In addition, regulatory frameworks for oligonucleotide-based therapeutics vary across countries, creating hurdles for companies aiming to expand regionally without encountering compliance delays
• The requirement for stringent quality control, particularly for clinical-grade oligonucleotides used in therapeutics, increases the need for advanced instrumentation and skilled personnel, further adding to costs.
• Moreover, concerns regarding intellectual property protection in certain countries can dissuade foreign investment and limit the willingness of global players to share proprietary synthesis technologies

Asia-Pacific Oligonucleotides Synthesis Market Scope

The market is segmented on the basis of product type, application, and end-user.

• By Product Type

On the basis of product type, the Asia-Pacific oligonucleotides synthesis market is segmented into synthesized oligonucleotide products, reagents, equipment, and services. The synthesized oligonucleotide products segment held the largest market share of 49.50% in 2024, driven by their wide application in PCR, sequencing, gene editing, and other molecular biology procedures. These products are essential for both research and therapeutic development across academic and commercial sectors.

The services segment is anticipated to witness the fastest growth with an estimated CAGR of 12.8% from 2025 to 2032, as outsourcing trends increase among pharmaceutical companies and academic institutions for cost-effective and customized oligo synthesis.

• By Application

On the basis of application, the Asia-Pacific oligonucleotides synthesis market is segmented into research, therapeutics, and diagnostics. The research segment held the largest share of 48.2% in 2024, primarily due to the rising volume of genetic and genomic studies, particularly in university and government-funded research organizations.

The therapeutics segment is projected to grow at the fastest rate with a CAGR of 13.4%, fueled by the increasing clinical adoption of oligonucleotide-based drugs targeting genetic disorders and cancers.

• By End-User

On the basis of end-user, the Asia-Pacific oligonucleotides synthesis market is segmented into academic research institutes, pharmaceutical and biotechnology companies, and hospital and diagnostic laboratories. The pharmaceutical and biotechnology companies segment held the largest share of 46.1% in 2024, owing to high R&D spending on gene therapies, vaccine development, and precision medicine.

The hospital and diagnostic laboratories is expected to witness the fastest CAGR from 2025 to 2032, driven by the growing demand for molecular diagnostics and increasing incidence of infectious and chronic diseases.

Asia-Pacific Oligonucleotides Synthesis Market Regional Analysis

• Asia-Pacific held a market share of 38.6% in oligonucleotides synthesis market, driven by increasing investments in biotechnology, expanding pharmaceutical manufacturing capabilities, and the growing focus on genomics and precision medicine in countries such as China, Japan, South Korea, and India
• The region benefits from a strong presence of contract research organizations (CROs), favorable government funding for life sciences research, and a rising number of academic collaborations that fuel demand for oligonucleotide synthesis across research and therapeutic domains
• In addition, the surging burden of chronic and genetic diseases has accelerated the adoption of advanced molecular diagnostics and targeted therapies, positioning the Asia-Pacific region as a vital hub for oligonucleotide development and application across both public and private healthcare sector

India Oligonucleotides Synthesis Market Insight

The India oligonucleotides synthesis market is witnessing a rapid rise in demand for oligonucleotide synthesis, primarily driven by its expanding pharmaceutical industry, increasing focus on genomic research, and strong support through national biotechnology initiatives. Its growing population, increased funding in R&D, and emerging presence in contract research and manufacturing services make it the fastest-growing market in the region, with a CAGR of 14.2% from 2025 to 2032.

China Oligonucleotides Synthesis Market Insight

The China oligonucleotides synthesis market is the dominant market in the Asia-Pacific region with 37.5% revenue share in 2024. Its leadership is supported by large-scale production facilities, growing domestic demand for precision medicine, and active government initiatives in synthetic biology. With increasing applications in diagnostics, therapeutics, and agriculture, China continues to be the primary revenue contributor in the regional landscape

Japan Oligonucleotides Synthesis Market Insight

The Japan oligonucleotides synthesis market is characterized by high adoption of genomic technologies, a strong pharmaceutical sector, and a growing elderly population seeking precision healthcare. The country is making strides in oligonucleotide-based drug development and diagnostic tools, contributing substantially to the regional market. Japan is expected to maintain a healthy growth rate with a projected CAGR of around 11.3% from 2025 to 2032.

South Korea Oligonucleotides Synthesis Market Insight

The South Korea oligonucleotides synthesis market is emerging as a key regional player with rising investments in biotechnology, innovation-driven academic institutions, and public-private partnerships. The country’s oligonucleotide synthesis market is expected to grow at a CAGR of 12.1%, driven by strong biomedical R&D and growing demand for advanced diagnostics and therapeutics.

Asia-Pacific Oligonucleotides Synthesis Market Share

The Asia-Pacific oligonucleotides synthesis industry is primarily led by well-established companies, including:

• Thermo Fisher Scientific Inc. (U.S.)
• Merck KGaA (U.S.)
• GE Healthcare (U.S.)
• Agilent Technologies, Inc. (U.S.)
• Bio-Synthesis, Inc. (U.S.)
• Kaneka Eurogentec S.A (Belgium)
• Integrated DNA Technologies, Inc. (U.S.)
• Biolegio (Netherlands)
• Twist Bioscience (U.S.)
• Danaher Corporation (U.S.)
• LGC Biosearch Technologies (U.K.)
• Sarepta Therapeutics, Inc. (U.S.)
• Maravai LifeSciences (U.S.)
• Eurofins Scientific (Luxembourg)
• GenScript (U.S.)

Latest Developments in Asia-Pacific Oligonucleotides Synthesis Market

• In May 2023, GenScript Biotech Corporation expanded its principal manufacturing plant for oligonucleotide production in Jiangsu, China. This expansion aims to meet the growing demand for oligos and peptides in the APAC region, supporting advancements in biopharma, particularly in molecular diagnostics, RNAi, and gene editing. The enhanced facility is equipped with state-of-the-art facilities and automated workstations, boosting capacity to meet diverse research and IVD (In Vitro Diagnostics) kit material needs
• In December 2024, Co-Diagnostics, Inc. and CoSara Diagnostics inaugurated a new oligonucleotide synthesis facility in Ranoli, India. This initiative supports the "Make in India" program and is designed to manufacture Co-Diagnostics' patented Co-Primers® chemistry, which is crucial for their lab-based PCR diagnostic tests. This development is expected to facilitate access to India's large healthcare market and enhance manufacturing efficiency
• In October 2023, Integrated DNA Technologies (IDT) opened a new therapeutic manufacturing facility to address the growing demand in genetic medicine. While the specific location for this facility is not explicitly stated as APAC in the provided snippets, IDT has a growing presence in the Asia-Pacific region, driven by increasing demand for precision diagnostics and therapeutic oligos. This facility is designed to enable the manufacture of therapeutic oligonucleotides, meeting the growing need in genomics and personalized medicine globally, with implications for APAC's expanding market
• In May 2023, Twist Bioscience and CeGaT GmbH collaborated to develop the Twist Alliance CeGaT RNA Fusion Panel, a specific tool for oncology research aimed at detecting RNA fusions and transcript variation analysis. Such collaborations, even if initiated outside APAC, contribute to the global advancement of oligonucleotide-based research tools which are increasingly adopted in the Asia-Pacific region's growing oncology research sector

SKU-45084